he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
- 2022-05-05癫痫患者的
- 2022-04-28病故中后癫痫首选用药有哪些?解答病故中后癫痫的4大问题
- 2022-04-272013年国际抗癫痫Federation抗癫痫药使用指南
- 2022-01-24癫痫病饮食精神科包含哪些内容
- 挑战PD-L1阴性:白全生物推动世界首创免疫检查点抑制剂研发
- 2013国际医疗器械创新创业合作论坛
- 月经提前的原因是什么?
- 非淋菌性炎的症状是什么
- 银屑病常用药物进入医疗保险,有效减轻患者的医疗负担
- Cell J:对比研究揭示了子宫内膜异位症的另一种可能机制
- 癫痫治疗障碍仍难以克服
- 疾病新知:毛囊性白癜风
- 李敖病逝!面对医疗展示勇士的姿态
- 「聚焦海扶刀」兵不刃血 轻松「切除」肾上腺
- 染发的危害 这样做可能会导致脱发
- J Allergy Clin Immunol:IgE对鼻息肉有影响吗?
- 更年期综合征妇女会遇到的问题
- 私密┃我说同房疼,医生说我有妇科病?
- BMC Urol:晚期癌症患者服用阿帕鲁胺后出现皮疹需要特殊治疗吗?
- JAMA:阳性结果的文章一定更受关注吗?
- 38癫痫患者年病史上的感谢信 道出了浓浓的医患情况
- 凹进去怎么办?会是乳腺癌吗?!
- 最新!最近,创新药获得了世界上第一批!
- BMJ:血浆置换对ANCA相关性血管炎患者的影响
- 睡觉时突然抽搐 新生儿睡觉抽搐怎么办?
- Alz Res Therapy:健康饮食可以降低痴呆的风险
- 医生拒绝医生拒绝做妇科手术,这层膜真的那么重要吗?
- 孩子脸上有白斑,肚子里有蛔虫?医生:不是蛔虫斑,可能是癌症
- 2019年10月19日Lancet研究精选
- A&R:洛西汀对髋关节或膝关节骨性关节炎慢性疼痛患者没有附加值
- 影响晨勃次数减少是否异常的四个因素,回答男性的问题
- 白癜风症状 有些白斑可以预防白癜风
- 早期小儿癫痫病有什么病征
- 怎么了解癫痫病的症状与病患
- 治疗女性癫痫病的多借钱
- 老年痴呆症病症 这些原因易使人患老年痴呆
- 哪里能化疗癫痫病
- 癫痫病的病症有哪些呢
- 国内治疗癫痫病医务人员
- 最佳癫痫病用药方法症状是什么
- 癫痫病是怎么惹来的发病 癫痫病的病因是什么
- 疗法癫痫病的最佳医院
- 用药癫痫病方法哪种最有效
- 中医治疗癫痫病比较好疗养院